Medidata recommits to Catalyst Clinical Research expanding multi-year partnership
The Dassault Systèmes company is a provider of clinical trial solutions to the life sciences industry and announced the multi-year partnership expansion on October 26.
The companies have already got an existing successful relationship with the intention of building upon this by incorporating wider offerings including Medidata Grants Manager and Medidata AI Intelligent Trials to support Catalyst’s growth into a full-service clinical research organization (CRO).
This continued commitment to Medidata Rave EDC, Medidata Rave CTMS, and Medidata Rave eTMF, should enable Catalyst to run complex clinical trials while at the same time simplifying its operations and management.
By using these integrated capabilities and incorporating the expansive elements of Grants Manager and Intelligent Trials, Catalyst can streamline workflows, automate document management, and improve visibility to critical trial metrics.
Advanced tech supports growth and expansion
“Medidata remains our preferred partner because of their scalability and skill in managing complex trials,” said Nik Morton, president, and chief operating officer, at Catalyst.
"Their advanced technology will further support our growth and expansion."
So far, Catalyst has supported over 150 oncology studies and is currently managing more than 80 next-generation cancer clinical trials today across phases 1-3. With 90% of all oncology approvals last year in the US developed using Medidata software, Catalyst’s use of the Medidata platform will be critical to its continued expansion. In addition, Catalyst is excited to leverage Medidata AI, which accesses a dataset spanning more than 20 years to engage a more diverse patient population and accelerate enrollment.
“Medidata is thrilled to serve as Catalyst’s partner since their first trial in 2019 and be part of their continued success,” said Joan Shaiman, senior vice president, Partners, Medidata.
“Their decision to recommit to the core elements of our platform and adopt broader solutions demonstrates that we have the expertise and capabilities needed to support faster decision-making and accelerate trials to advance cancer research.”
The company’s platform is dedicated to clinical research and aims to help life science and medical device organizations cut development costs, mitigate risks, and deliver treatments and devices to market faster. It enables central management of sites, users, and roles across studies and applications. Users can add or update site information once and it is automatically available for use across all Medidata’s applications. Using the platform means an end to reconciling entries or contact information across multiple systems and locations and is designed to save time, reduce effort and eliminate errors.
